Hematopoietic growth factors, version 1.2020: Featured updates to the NCCN guidelines Guidelines
| Authors: | Becker, P. S.; Griffiths, E. A.; Alwan, L. M.; Bachiashvili, K.; Brown, A.; Cool, R.; Curtin, P.; Dinner, S.; Gojo, I.; Hicks, A.; Kallam, A.; Kidwai, W. Z.; Kloth, D. D.; Kraut, E. H.; Landsburg, D.; Lyman, G. H.; Miller, R.; Mukherjee, S.; Patel, S.; Perez, L. E.; Poust, A.; Rampal, R.; Rosovsky, R.; Roy, V.; Rugo, H. S.; Shayani, S.; Vasu, S.; Wadleigh, M.; Westbrook, K.; Westervelt, P.; Burns, J.; Keller, J.; Pluchino, L. A. |
| Title: | Hematopoietic growth factors, version 1.2020: Featured updates to the NCCN guidelines |
| Abstract: | Management of febrile neutropenia (FN) is an integral part of supportive care for patients undergoing cancer treatment. The NCCN Guidelines for Hematopoietic Growth Factors provide suggestions for appropriate evaluation, risk determination, prophylaxis, and management of FN. These NCCN Guidelines are intended to guide clinicians in the appropriate use of growth factors for select patients undergoing treatment of nonmyeloid malignancies. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines regarding the incorporation of newly FDA-approved granulocyte-colony stimulating factor biosimilars for the prevention and treatment of FN. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. |
| Journal Title: | Journal of the National Comprehensive Cancer Network |
| Volume: | 18 |
| Issue: | 1 |
| ISSN: | 1540-1405 |
| Publisher: | Harborside Press |
| Date Published: | 2020-01-01 |
| Start Page: | 12 |
| End Page: | 22 |
| Language: | English |
| DOI: | 10.6004/jnccn.2020.0002 |
| PUBMED: | 31910384 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Source: Scopus |
